Table 4 Health care resource utilization
From: Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
HCRU, mean (SD) | All patients (N = 172) | Max | P valuea |
|---|---|---|---|
Mean hospitalizations (per month) | |||
Pre-index | 0.21 (0.79) | 6.00 | |
Post-index | 0.16 (0.60) | 4.38 | 0.095 |
Mean hospitalization cost (per month) | |||
Pre-index | $2051.91 (10,003.23) | $93,688.35 | |
Post-index | $1359.88 (6261.61) | $55,951.04 | 0.232 |
Mean ER visits (per month) | |||
Pre-index | 0.72 (1.26) | 7.50 | |
Post-index | 0.54 (0.89) | 5.36 | 0.003 |
Mean ER visit costs (per month) | |||
Pre-index | $1300.89 (4377.38) | $47,351.24 | |
Post-index | $1258.30 (5966.90) | $73,758.67 | 0.825 |
Mean outpatient visits (per month) | |||
Pre-index | 1.04 (1.19) | 7.50 | |
Post-index | 0.81 (0.87) | 5.36 | < 0.001 |
Mean outpatient visit costs (per month) | |||
Pre-index | $531.21 (1067.18) | $6246.26 | |
Post-index | $697.63 (1665.83) | $14,182.75 | 0.257 |
Mean outpatient visit costs (per month) without outliers (i.e., restricting data to cost ≤$5000.00) | |||
Pre-index | $465.96 (898.96) | $4813.15 | |
Post-index | $459.14 (823.01) | $4477.17 | 0.935 |